Cytek Biosciences, Inc. CTKB Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $44.14M-29.0% | $62.14M+18.8% | $52.29M+14.7% | $45.6M+10.0% | $41.46M-27.9% | ||
| $22.88M-21.8% | $29.26M+18.2% | $24.74M+13.8% | $21.74M+2.0% | $21.3M-10.6% | ||
| $21.25M-35.4% | $32.89M+19.4% | $27.55M+15.4% | $23.87M+18.4% | $20.16M-40.1% | ||
| 48.2%-4.8pp | 52.9%+0.2pp | 52.7%+0.3pp | 52.3%+3.7pp | 48.6%-9.9pp | ||
| $9.6M+7.2% | $8.96M+0.1% | $8.96M+1.5% | $8.83M-9.2% | $9.73M0.0% | ||
| $11.65M-11.3% | $13.13M+12.6% | $11.67M-3.9% | $12.13M-3.0% | $12.51M+5.3% | ||
| $18.47M+12.7% | $16.39M+1.6% | $16.12M+19.1% | $13.53M+4.9% | $12.9M+42.2% | ||
| $39.72M+3.2% | $38.48M+4.7% | $36.74M+6.5% | $34.49M-1.8% | $35.13M+14.6% | ||
| -$18.46M-230% | -$5.59M+39.1% | -$9.19M+13.5% | -$10.62M+29.1% | -$14.98M— | ||
| -41.8%-32.8pp | -9%+8.6pp | -17.6%+5.7pp | -23.3%+12.8pp | -36.1%— | ||
| $262K— | —— | $494K+19.3% | $414K+42.3% | $291K+105% | ||
| $1.09M-30.3% | $1.56M+9.8% | $1.42M-63.0% | $3.85M+3.8% | $3.71M-49.4% | ||
| $1.49M-96.3% | $40.05M+1,848% | -$2.29M-92.2% | -$1.19M-976% | $136K-80.0% | ||
| -$18.87M+57.2% | -$44.08M-705% | -$5.48M+1.9% | -$5.58M+51.0% | -$11.4M— | ||
| -42.7%+28.2pp | -70.9%-60.5pp | -10.5%+1.8pp | -12.2%+15.3pp | -27.5%— | ||
| -$0.15+55.9% | -$0.34-750% | -$0.040.0% | -$0.04+55.6% | -$0.09— | ||
| -$16.6M-349% | -$3.7M+49.2% | -$7.27M+16.7% | -$8.73M+33.3% | -$13.1M— | ||
| -37.6%-31.7pp | -6%+8.0pp | -13.9%+5.2pp | -19.2%+12.4pp | -31.6%— | ||
| -$18.46M-230% | -$5.59M+39.1% | -$9.19M+13.5% | -$10.62M+29.1% | -$14.98M— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Cytek Biosciences, Inc.'s revenue?
- Cytek Biosciences, Inc. (CTKB) generated $204.2M in revenue over the trailing twelve months, up 3.6% year over year.
- Is Cytek Biosciences, Inc. profitable?
- Cytek Biosciences, Inc. is not currently profitable: it reported a net loss of $74.0M over the trailing twelve months, a -36.2% net margin.
- What are Cytek Biosciences, Inc.'s profit margins?
- Gross margin is 51.7% and operating margin is -21.5%, with a -36.2% net margin.
- What is Cytek Biosciences, Inc.'s earnings per share?
- Cytek Biosciences, Inc.'s diluted EPS over the trailing twelve months is $-0.57.
- Where does Cytek Biosciences, Inc.'s income statement data come from?
- Every line is extracted from Cytek Biosciences, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
